PMID- 36591513
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20230103
IS  - 2234-943X (Print)
IS  - 2234-943X (Electronic)
IS  - 2234-943X (Linking)
VI  - 12
DP  - 2022
TI  - EWSR1::SMAD3-rearranged fibroblastic tumor: A case with twice recurrence and 
      literature review.
PG  - 1017310
LID - 10.3389/fonc.2022.1017310 [doi]
LID - 1017310
AB  - EWSR1::SMAD3-rearranged fibroblastic tumor is a recently described entity that 
      mostly occurs in acral locations. Only 15 cases have been reported in the English 
      literature, with a wide age range and marked female predominance. The most common 
      sites are the foot, followed by the hand and the distal lower leg. There are four 
      cases that recurred locally during 5-120 months of follow-up, with no metastases 
      to date. Herein, we presented a case of EWSR1::SMAD3-rearranged fibroblastic 
      tumor that recurred twice in a 20-year-old man. The patient presented with a 
      second recurrent painful nodule in the left plantar of the second toe. Grossly, 
      the lesion was pale solid and well-defined, measuring 9 x 8 x 9 mm in size. 
      Histological examination revealed a monomorphic spindle cell tumor composed of 
      cellular fascicles of bland fibroblasts in a collagenous to myxoid stroma with 
      low mitotic activity, which evoked a wide spectrum of differential diagnoses. 
      Immunohistochemically, the tumor cells were diffusely and strongly positive for 
      ERG while negative for S100, alpha-SMA, CD34, and other vascular markers. An 
      unbalanced rearrangement of EWSR1 was demonstrated by fluorescence in situ 
      hybridization (FISH), and a gene fusion between EWSR1 exon 7 and SMAD3 exon 6 was 
      confirmed by RT-PCR and Sanger sequencing. This case recurred twice within 6 
      years with no sign of further relapse and metastasis at another 9-month follow-up 
      since the last surgery, indicating that this tumor was benign but prone to local 
      recurrence. Nevertheless, more cases and further studies are needed to better 
      interpret the biological behavior of this new entity.
CI  - Copyright (c) 2022 Yang, Fan, Yin, Liu, Zhao, Wang and Cheng.
FAU - Yang, Li
AU  - Yang L
AD  - State Key Laboratory of Cancer Biology, Department of Pathology, Xijing Hospital 
      and School of Basic Medicine, Fourth Military Medical University (Air Force 
      Medical University), Xi'an, China.
FAU - Fan, Linni
AU  - Fan L
AD  - State Key Laboratory of Cancer Biology, Department of Pathology, Xijing Hospital 
      and School of Basic Medicine, Fourth Military Medical University (Air Force 
      Medical University), Xi'an, China.
FAU - Yin, Zhiyong
AU  - Yin Z
AD  - Department of Cardiology, Xijing Hospital, Fourth Military Medical University 
      (Air Force Medical University), Xi'an, China.
FAU - Liu, Yixiong
AU  - Liu Y
AD  - State Key Laboratory of Cancer Biology, Department of Pathology, Xijing Hospital 
      and School of Basic Medicine, Fourth Military Medical University (Air Force 
      Medical University), Xi'an, China.
FAU - Zhao, Danhui
AU  - Zhao D
AD  - State Key Laboratory of Cancer Biology, Department of Pathology, Xijing Hospital 
      and School of Basic Medicine, Fourth Military Medical University (Air Force 
      Medical University), Xi'an, China.
FAU - Wang, Zhe
AU  - Wang Z
AD  - State Key Laboratory of Cancer Biology, Department of Pathology, Xijing Hospital 
      and School of Basic Medicine, Fourth Military Medical University (Air Force 
      Medical University), Xi'an, China.
FAU - Cheng, Hong
AU  - Cheng H
AD  - State Key Laboratory of Cancer Biology, Department of Pathology, Xijing Hospital 
      and School of Basic Medicine, Fourth Military Medical University (Air Force 
      Medical University), Xi'an, China.
LA  - eng
PT  - Case Reports
DEP - 20221215
PL  - Switzerland
TA  - Front Oncol
JT  - Frontiers in oncology
JID - 101568867
PMC - PMC9798226
OTO - NOTNLM
OT  - ERG
OT  - EWSR1
OT  - SMAD3
OT  - case report
OT  - fibroblastic tumor
COIS- The authors declare that the research was conducted in the absence of any 
      commercial or financial relationships that could be construed as a potential 
      conflict of interest.
EDAT- 2023/01/03 06:00
MHDA- 2023/01/03 06:01
PMCR- 2022/01/01
CRDT- 2023/01/02 04:57
PHST- 2022/08/11 00:00 [received]
PHST- 2022/11/25 00:00 [accepted]
PHST- 2023/01/02 04:57 [entrez]
PHST- 2023/01/03 06:00 [pubmed]
PHST- 2023/01/03 06:01 [medline]
PHST- 2022/01/01 00:00 [pmc-release]
AID - 10.3389/fonc.2022.1017310 [doi]
PST - epublish
SO  - Front Oncol. 2022 Dec 15;12:1017310. doi: 10.3389/fonc.2022.1017310. eCollection 
      2022.